Kezar Life Sciences, Inc.

DB:2KZ0 Stock Report

Market Cap: €51.1m

Kezar Life Sciences Management

Management criteria checks 2/4

Kezar Life Sciences' CEO is Chris Kirk, appointed in Nov 2023, has a tenure of 9.75 years. total yearly compensation is $2.60M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth €302.12K. The average tenure of the management team and the board of directors is 2 years and 7.5 years respectively.

Key information

Chris Kirk

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage9.3%
CEO tenureless than a year
CEO ownership0.6%
Management average tenure2yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Kirk's remuneration changed compared to Kezar Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$96m

Jun 30 2024n/an/a

-US$99m

Mar 31 2024n/an/a

-US$101m

Dec 31 2023US$3mUS$242k

-US$102m

Sep 30 2023n/an/a

-US$88m

Jun 30 2023n/an/a

-US$83m

Mar 31 2023n/an/a

-US$74m

Dec 31 2022US$2mUS$468k

-US$68m

Sep 30 2022n/an/a

-US$64m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$58m

Dec 31 2021US$2mUS$443k

-US$55m

Sep 30 2021n/an/a

-US$51m

Jun 30 2021n/an/a

-US$48m

Mar 31 2021n/an/a

-US$45m

Dec 31 2020US$880kUS$426k

-US$42m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$37m

Dec 31 2019US$2mUS$410k

-US$35m

Sep 30 2019n/an/a

-US$31m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$962kUS$365k

-US$23m

Sep 30 2018n/an/a

-US$20m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$745kUS$325k

-US$9m

Compensation vs Market: Chris's total compensation ($USD2.60M) is above average for companies of similar size in the German market ($USD476.59K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Kirk (52 yo)

less than a year

Tenure

US$2,602,155

Compensation

Dr. Christopher J. Kirk, also known as Chris, Ph.D. serves as Member of Scientific Advisory Board at Rain Oncology Inc. (formerly known as Rain Therapeutics Inc.) He is a Co-Founder of Kezar Life Sciences,...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Kirk
Co-Founderless than a yearUS$2.60m0.59%
€ 302.1k
John Fowler
Co-Founder & Directorno dataUS$4.83m0.60%
€ 305.5k
Marc Belsky
CFO & Secretary6.7yrsUS$2.01m0.026%
€ 13.1k
Jack Taunton
Co-Founderno datano datano data
Gitanjali Jain
Senior Vice President of Investor Relations & External Affairsno datano datano data
Mark Schiller
Chief Legal Officer5.6yrsno data0.025%
€ 12.6k
Joe Tedrick
Vice President of Human Resourcesless than a yearno datano data
Neel Anand
Senior Vice President of Research & Drug Discovery2.6yrsno datano data
Zung To
Senior Vice President of Clinical Development1.5yrsno datano data
Pattie Chiang
Senior VP & Corporate Controllerno datano datano data

2.0yrs

Average Tenure

52yo

Average Age

Experienced Management: 2KZ0's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Kirk
Co-Founder9.8yrsUS$2.60m0.59%
€ 302.1k
John Fowler
Co-Founder & Director9.8yrsUS$4.83m0.60%
€ 305.5k
Michael Kauffman
Independent Director7.9yrsUS$155.34k0.087%
€ 44.6k
Franklin Berger
Independent Director8.8yrsUS$141.22k1.22%
€ 623.9k
Graham Cooper
Independent Chairman7.1yrsUS$194.56k0%
€ 0
Elizabeth Ijeoma Garner
Independent Director4.9yrsUS$149.45k0%
€ 0
Courtney Wallace
Independent Director2.9yrsUS$164.59k0%
€ 0
Micki Klearman
Independent Director3.4yrsUS$161.58k0%
€ 0

7.5yrs

Average Tenure

54yo

Average Age

Experienced Board: 2KZ0's board of directors are considered experienced (7.5 years average tenure).